Transthyretin AmyloidosisTRAMmoniTTRNCT03237494
TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects
An observational study of Transthyretin Amyloidosis and Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, run by CENTOGENE GmbH Rostock at 84 sites in 3 countries.
Trial summary
National, multicenter, epidemiological, longitudinal protocol to investigate the hATTR prevalence in an at-risk population for Hereditary Transthyretin Amyloidosis (hATTR) and subjects diagnosed with hATTR, to monitor the clinical status in TTR positive subjects and to establish hATTR biomarker/s Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Transthyretin Amyloidosis, Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy
- How many people
- 5,028 participants
- Where
- 84 sitesin 3 countries
- Study dates
- 20 Jul 2017to 16 May 2025
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants at risk for Hereditary Transthyretin Amyloidosis (hATTR) and participants diagnosed with hATTR
Who may be able to join
- Informed consent is obtained from the participant
- The participant is 18 years of age or older
- The participant has no diagnosis of alcoholism according to international guidelines
- The participant has not undergone chemotherapy for any carcinoma
- AND
- The participant is at risk for hATTR due to two or more the factors listed below:
Show all 20Show fewer
- cardiomyopathy or polyneuropathy with no obvious etiology atypical Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Motor Neuron Disease (MND)
- autonomic dysfunction
- hypertrophic cardiomyopathy or heart failure with preserved ejection fraction Left Ventricular Hypertrophy (LVH)
- bilateral carpal tunnel syndrome
- spinal stenosis or spinal radiculopathy
- gait disorders
- ocular changes involving vitreous opacities
- unexplained weight loss >5kg
- renal abnormalities
- family history of hATTR
- based on imaging or biopsy suspected for the wild type TTR (ATTR) and not genetically tested for hATTR
- OR • The participant is diagnosed with hATTR
- OR
- The participant is a 1st or 2nd degree relative of the TTR positive subject
Who cannot join
- Informed consent is not obtained from the participant
- The participant is younger than 18 years of age
- The participant has a diagnosis of alcoholism according to International guidelines
- The participant has undergone chemotherapy for any carcinoma
- The participant is not at risk for hATTR
Trial locations and contacts
84 sites in 3 countries.
84 sites in 3 countries
Germany79 sites
Universitätsklinikum Aachen, Neurology
Aachen, 52074
Klinikum Westmünsterland GmbH, I. Medizinische Klinik und Interventionelle Kardiologie
Ahaus, 48683
Kreiskrankenhaus Altenburg, Neurology
Altenburg, 04600
Sächsisches Krankenhaus Arnsdorf, Akademisches Lehrkrankenhaus der TU Dresden, Neurology
Arnsdorf, 01477
Gemeinschaftspraxis Neurologie & Psychiatrie im Stadtpalais
Aschaffenburg, 63739
Kerckhoff-Klinik GmbH, Klinik für Kardiologie, Cardiology
Bad Nauheim, 61231
RHÖN-KLINIKUM Campus Bad Neustadt, Neurology
Bad Neustadt an der Saale, 97616
Charité - Universitätsmedizin Berlin Funktionsdiagnostik und Stationen, Cardiology
Berlin, 10117
Charité Universitätsmedizin Berlin, Klinik für Neurologie, Neurology
Berlin, 10117
Sana Klinikum Lichtenberg
Berlin, 101365
Charité Universitätsmedizin Berlin - Campus Virchow Klinikum (CVK), Cardiology
Berlin, 13353
Klinikum Bielefeld, Klinik für Kardiologie und internistische Intensivmedizin, Cardiology
Bielefeld, 33604
Evangelisches Klinikum Bethel gGmbH v. Bodelschwinghsche Stiftungen Bethel, Neurology
Bielefeld, 33617
Klinikum Bremen Mitte gGmbH, Neurologische Klinik, Neurology
Bremen, 28177
Gesundheit Nord gGmbH - Klinikverband Bremen
Bremen, 28211
Krankenhaus Buchholz und Winsen, gemeinnützige GmbH, Cardiology
Buchholz in der Nordheide, 21244
Krankenhaus Buchholz und Winsen, gemeinnützige GmbH, Neurology
Buchholz in der Nordheide, 21244
Allgemeines Krankenhaus Celle, Neurology
Celle, 29223
Carl-Thiem-Klinikum Cottbus gGmbH
Cottbus, 03048
St. Vincenz Krankenhaus Datteln, Medizinische Klinik II, Cardiology
Datteln, 45711
Klinikum Dortmund gGmbH,Stroke-Unit und Neurologische Intensivstation, Neurology
Dortmund, 44137
LVR Klinikum Düsseldorf, Neurology
Düsseldorf, 40629
Martin Gropius Krankenhaus, Klinik für Neurologie, Neurology
Eberswalde, 16225
Universitätsklinikum Erlangen, Cardiology
Erlangen, 91045
Alfried Krupp Krankenhaus Rüttenscheid, Neurology
Essen, 45131
Contilia Herz- und Gefäßzentrum, Elisabeth-Krankenhaus Essen, Cardiology
Essen, 45138
Kliniken an der Paar Friedberg Krankenhaus, Cardiology
Friedberg, 86316
Herz-Thorax-Zentrum Fulda, Klinikum Fulda gAG, Universitätsmedizin Marburg - Campus Fulda, Cardiology
Fulda, 36043
University of Giessen-Marburg, Neurology
Giessen, D-35385
Universitätsmedizin Göttingen - Herzzentrum; Cardiology
Göttingen, 37075
Universitätsklinikum Greifswald der Ernst-Moritz-Arndt-Universität, Neurology
Greifswald, 17489
kbo-Isar-Amper-Klinikum München-Ost, Klinik für Neurologie, Neurology
Haar, 85540
Martin-Luther-Universität, Universitätsklinik und Poliklinik für Neurologie, Neurology
Halle, 06120
Universitätsklinik und Poliklinik für Innere Medizin III, Cardiology
Halle, 06120
Asklepios Klinik St. Georg, Klinik für Neurologie
Hamburg, 20099
Universitäres Herzzentrum Hamburg, Klinik für Allgemeine und Interventionelle Kardiologie, Universitätsklinikum Hamburg-Eppendorf, Cardiology
Hamburg, 20246
Neurologie Neuer Wall, Fachärzte für Neurologie & Psychiatrie, Neurology
Hamburg, 20354
Albertinen-Krankenhaus, Cardiology
Hamburg, 22457
Asklepios Klinik Altona, Neurologische Abteilung mit überregionaler Stroke Unit, Neurophysiologie und Neurologischer Intensivmedizin
Hamburg, 22763
Medizinische Hochschule Hannover, Klinik für Neurologie; Neurology
Hanover, 30625
Universitätsklinikum Heidelberg, Klinik für Kardiologie, Angiologie und Pneumologie, Cardiology
Heidelberg, 69120
Lausitzer Seenland Klinikum GmbH, Klinik für Neurologie, Neurology
Hoyerswerda, 02977
Universitätsklinikum Jena, Neurology
Jena, 07740
Universitätsklinikum Jena Klinik für Innere Medizin I
Jena, 07747
DRK-Kliniken Nordhessen gGmbH , Klinik für Neurologie und Klinische Neurophysiologie, Neurology
Kassel, 34121
Alexianer Krefeld GmbH, Krankenhaus Maria Hilf, Neurology
Krefeld, 47805
Universitaetsklinikum Leipzig, Neurology
Leipzig, 04103
Klinikum St. Georg gGmbH
Leipzig, 04129
Universitäres Herzzentrum Lübeck, Medizinische Klinik II
Lübeck, 23538
Sana Kliniken Lübeck GmbH, Medizinische Klinik II
Lübeck, 23560
Universitätsklinikum Schleswig-Holstein
Lübeck, 23562
Asklepios Fachklinikum Lübben, Neurology
Lubin, 15907
DRK Schmerz-Zentrum, Neurology
Mainz, 55131
Johannes Gutenberg-Universität Mainz, Klinik und Poliklinik für Neurologie; Neurology
Mainz
Diakonissen Speyer-Mannheim, Diakonissenkrankenhaus Mannheim, Neurology
Mannheim, 68163
Neckar-Odenwald Kliniken gGmbH, Kreiskrankenhaus Mosbach, Kardiologie der Klinik für Innere Medizin
Mosbach, 74821
Ökumenisches Hainich Klinikum gGmbH, Neurology
Mühlhausen, 99974
Friedrich-Baur-Institut, Neurologische Klinik und Poliklinik, Neurology
München, 80336
Kardiologie München Nord, Cardiology
München, 80939
Ludwig-Maximilians-Universität München, Klinikum Großhadern, Neurologische Klinik und Poliklinik & Deutsches Schwindel- und Gleichgewichtszentrum DSGZ, Neurology
München, 81377
Klinik und Poliklinik für Neurologie, Klinikum rechts der Isar, Technische Universität München
München, 81675
Praxis für Neurologie, Neurology
München, 81825
Ruppiner Kliniken GmbH,Hochschulklinikum der MHB, Neurology
Neuruppin, 16816
UKRB Universitätsklinikum Ruppin Brandenburg
Neuruppin, 16816
Kreiskrankenhaus Prignitz gGmbH, Neurology
Perleberg, 19348
Krankenhaus Barmherzige Brüder Regensburg, Klinik für Neurologie, Neurology
Regensburg, 93049
Universitätsklinikum Regensburg, Cardiology
Regensburg, 93053
Nordwest-Krankenhaus Sanderbusch gGmbH, Neurologische Klinik, Neurology
Sande, 26452
Sächsisches Krankenhaus Altscherbitz, Neurology
Schkeuditz, 04435
Jung-Stilling Klinikum Siegen, Diakonie Westfalen Süd Neuro, Neurogeriatrie, Neurology
Siegen, 57074
Elbe Klinikum Stade
Stade, 21682
Asklepios Fachklinikum Teupitz, Neurology
Teupitz, 15755
Universitätsklinikum Tübingen, Zentrum für Neurologie
Tübingen, 72076
NeuroPoint, Neurology
Ulm, 89073
University of Ulm, Neurology
Ulm, 89081
Sophien-u.Hufeland-Klinikum, Klinik für Neurologie und Klinische Neurophysiologie, Neurology
Weimar, 99425
Fachkrankenhaus Hubertusburg gGmbH, Neurologische Klinik, Neurology
Wermsdorf, 04779
Sana HANSE Klinikum Wismar, Klinik für Neurologie, Neurology
Wismar, 23966
Praxis für Neurologie, Neurology
Wolfratshausen, v
Switzerland3 sites
Luzerner Kantonspital, Cardiology
Lucerne, 6000
Solothurner Spitäler AG, Bürgerspital Solothurn, Cardiology
Olten, 4500
Praxisgemeinschaft für Kardiologie, Innere Medizin und Psychosomatische Medizin, Cardiology
Zug, 6300
Austria2 sites
Kepler Universitätsklinikum, Klinik für Interne 1 - Kardiologie und internistische Intensivmedizin; Cardiology
Linz, 4021
Kepler Universitätsklinikum, Neuromed Campus; Neurology
Linz, 4021
About this study
Official title: Genetic Screening of an At-risk Population for Hereditary TransthyRetin-related AMyloidosis and Longitudinal Monitoring of TTR Positive Subjects- A Multicenter Epidemiological Longitudinal Protocol
National, multicenter, epidemiological, longitudinal protocol to investigate the hATTR prevalence in an at-risk population for Hereditary Transthyretin Amyloidosis (hATTR) and subjects diagnosed with hATTR, to monitor the clinical status in TTR positive subjects and to establish hATTR biomarker/s
Read the detailed description
Hereditary TransThyRetin Amyloidosis (hATTR) is a slowly progressive condition, that is transmitted as an autosomal dominant trait and is characterized by abnormal extracellular deposits of fibrillar, misfolded proteins (amyloid fibrils) in the body. Amyloid fibrils can be deposited in different body compartments, such as the nerves, heart, gastrointestinal tract, kidneys and brain, causing severe structural changes. More than 30 proteins can trigger the formation of amyloid fibrils, 5 of which can infiltrate the heart and cause cardiac amyloidosis.
One of these amyloidogenic protein is transthyretin, formerly known as prealbumin. Transthyretin (TTR) is found primarily in the serum (secreted by the liver) and cerebrospinal fluid (secreted by the choroid plexus) and functions as a carrier for the hormone thyroxine (T4) and retinol-binding protein (bound to retinol or vitamin A). The destabilization of the TTR protein and the formation of misfolded TTR.
It is the goal of this study to investigate the prevalence of Hereditary Transthyretin-related Amyloidosis (hATTR) in a cohort of 5.000 subjects are at risk for Hereditary Transthyretin Amyloidosis (hATTR) and subjects diagnosed with hATTR, to monitor the clinical status in TTR positive subjects and to establish hATTR biomarker/s.
- Conditions
- Transthyretin Amyloidosis, Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Polyneuropathies, Cardiomyopathies
- Keywords
- Peripheral Nervous System Diseases, Transthyretin Amyloidosis, Transthyretin-related familial amyloid polyneuropathy, Transthyretin-related familial amyloid cardiomyopathy
- Medical subject headings
- Amyloidosis, Hereditary, Transthyretin-Related, Amyloid Neuropathies, Familial, Polyneuropathies, Cardiomyopathies, Peripheral Nervous System Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Participants at risk for hATTR and participants diagnosed with hATTR | Participants 18 years of age or older |
What is being measured
The primary outcome is the main question the study is designed to answer.
Analysis of prevalance of hATTR mutations among a cohort of participants at risk for hATTR.
DBS-based genetic analyses of TTR gene will be perfomed via the combination of the Next-Generation Sequencing (the mutation will be confirmed by Sanger sequencing) and the Multiplex ligation-dependent probe amplification.
Measured: 4 years
To monitor clinical status in TTR positive subjects.
8 Follow up visits within 24 months
Measured: 4 years
Secondary outcomes (1)
Establishment of biomarker/s in TTR positive cohort.
hATTR-positive samples will be analyzed for the identification of potential biomarkers (based on MS/MS-Tandem spectroscopy) and compared with the merged control samples in order establish a HAE specific biomarker.
Measured: 4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Aug 2017
- Study start20 Jul 2017
- Primary completion16 May 2025
- Study completion16 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Transthyretin AmyloidosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 5,028 participants (actual)
Sponsor and investigators
- Lead sponsor
- CENTOGENE GmbH Rostock
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Alnylam Pharmaceuticals
- Responsible party
- Sponsor
- Investigators
- Peter Bauer, Prof., Study chair, Centogene GmbH
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03237494
- Sponsor's protocol ID
- TRAM2 analysis
- Acronym
- TRAMmoniTTR
- Status last verified
- Sep 2024
- First submitted
- 31 Jul 2017
- Last updated
- 29 Jun 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No